[Summary] Adhering to the corporate culture of science and excellence, committed
Founded in 1998, Ganli Pharmaceutical Co., Ltd. is dedicated to the research, development, production, and sale of innovative drugs for the treatment of major diseases such as diabetes, tumors, and autoimmune diseases. On June 29, 2020, the company was listed on the main board of the Shanghai Stock Exchange, stock code: 603087.
Headquartered in Beijing, Ganli Pharmaceutical is a high-tech biopharmaceutical enterprise that has mastered the technology for industrial production of recombinant insulin analogues, with a complete insulin R&D pipeline. Currently, the company has five recombinant insulin analogue products: long-acting insulin glargine injection (Changxiulin), rapid-acting insulin lispro injection (Suxiulin), protamine zinc recombinant insulin lispro mixed injection (25R) (Suxiulin 25), insulin aspart injection (Ruixiulin), and insulin aspart 30 injection (Ruixiulin 30), covering the long-acting, rapid-acting, and intermediate-acting insulin market segments, as well as matching insulin injection pens and needles.
Since 2005, the company has leveraged its good product quality and advanced production technology to establish an international commercial network in more than 40 countries and regions worldwide, achieving rapid expansion in overseas markets. Meanwhile, the clinical trials of Ganli's insulin glargine, lispro, and aspart products in Europe and the United States are in the final stages, indicating that the company's products are about to be approved for marketing in developed countries such as Europe and the United States.
In the future, Ganli Pharmaceutical will achieve full coverage of its product line in the diagnosis and treatment of diabetes, further enhancing its market competitiveness in the diabetes treatment field. At the same time, it will actively invest in multiple research areas including oncology, tumors, and autoimmune diseases, providing diversified, high-quality pharmaceutical products and services to benefit more patients worldwide, and strive to become a leading pharmaceutical company.
Company official website:
What does Ganli Pharmaceutical Co., Ltd. require? Who is Ganli Pharmaceutical hiring? Ganli Pharmaceutical recruitment: 销售类占比最多占35.4%，其次是生物/制药/化工/环保类占29.8%. What education can get in at Ganli Pharmaceutical? 本科占比最多占37%，其次是硕士占26.8%. High education required at Ganli Pharmaceutical? 硕士占26.8%，博士占7.3%. Work experience required at Ganli Pharmaceutical? 1-3年占比最多占27.8%，其次是3-5年占26.8%. Where are the job locations at Ganli Pharmaceutical? 北京占比最多占33.5%，其次是临沂占4.6%. Based on job postings from the past year, for reference only.
Provided by
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows
Jobui does not provide an APP. Please follow our WeChat official account.
